CytoSorbents Reports Positive Growth and Regulatory Progress in 2025 Financial Results CytoSorbents Corporation has announced a 4% revenue increase and significant strides to bolster its regulatory efforts, marking a strong end to 2025.

CytoSorbents Reports Positive Growth and Regulatory Progress in 2025 Financial Results #United_States #Princeton #CytoSorbents #DrugSorb-ATR #Blood_Purification

CytoSorbents Engages in Virtual Fireside Chat to Discuss Future Growth and Innovations On December 15, 2025, CytoSorbents will hold a virtual fireside chat focusing on their innovative blood purification technologies and financial growth trajectory.

CytoSorbents Engages in Virtual Fireside Chat to Discuss Future Growth and Innovations #USA #Princeton #CytoSorbents #DrugSorb-ATR #Blood_Purification

CytoSorbents Prepares to Showcase Innovations at Jefferies Healthcare Conference in London CytoSorbents Corporation will present its breakthrough blood purification technologies at the upcoming Jefferies Global Healthcare Conference in London, highlighting advancements in critical care.

CytoSorbents Prepares to Showcase Innovations at Jefferies Healthcare Conference in London #London #United_Kingdom #Healthcare_Conference #CytoSorbents #Blood_Purification

CytoSorbents Delivers Strong Q3 2025 Results with Business Updates and Future Plans In Q3 2025, CytoSorbents saw a revenue growth of 10%, strengthened its balance sheet, and outlined strategic initiatives for future growth.

CytoSorbents Delivers Strong Q3 2025 Results with Business Updates and Future Plans #United_States #FDA_Approval #Princeton #CytoSorbents #DrugSorb-ATR

In Tribute to Dr. Robert Hawes Bartlett: Innovator in ECMO and Critical Care Medicine This article honors Dr. Robert Hawes Bartlett, a titan in critical care medicine and the father of ECMO, reflecting on his groundbreaking contributions and legacy.

In Tribute to Dr. Robert Hawes Bartlett: Innovator in ECMO and Critical Care Medicine #United_States #Princeton #CytoSorbents #ECMO #Robert_Bartlett

CytoSorbents Announces Regulatory Progress for DrugSorb-ATR Device CytoSorbents Corporation reports on the regulatory advancements for DrugSorb-ATR, a device aimed at enhancing patient safety during surgeries. This update highlights FDA interactions and future submission plans.

CytoSorbents Announces Regulatory Progress for DrugSorb-ATR Device #United_States #Princeton #FDA_Approvals #CytoSorbents #DrugSorb-ATR

CytoSorbents to Host Global Webinar Advancing Sepsis Treatment Insights on World Sepsis Day Join CytoSorbents on September 10, 2025, for a webinar discussing innovative strategies to combat sepsis and septic shock, highlighting valuable real-world insights.

CytoSorbents to Host Global Webinar Advancing Sepsis Treatment Insights on World Sepsis Day #United_States #Webinar #Princeton #sepsis #CytoSorbents

CytoSorbents Corporation to Showcase Innovations at H.C. Wainwright 27th Annual Global Investment Conference CytoSorbents Corporation is set to present at the H.C. Wainwright Conference, showcasing advancements in blood purification technology for critical care and surgery.

CytoSorbents Corporation to Showcase Innovations at H.C. Wainwright 27th Annual Global Investment Conference #United_States #New_York #CytoSorbents #Blood_Purification #CTSO

CytoSorbents Announces FDA Regulatory Update on DrugSorb-ATR Device Status CytoSorbents Corporation shares a regulatory update regarding the DrugSorb-ATR device status, detailing FDA's findings and future plans for market authorization.

CytoSorbents Announces FDA Regulatory Update on DrugSorb-ATR Device Status #United_States #FDA_Approval #Princeton #CytoSorbents #DrugSorb-ATR

CytoSorbents Announces Impressive Financial Growth in Second Quarter of 2025 In their recent report, CytoSorbents Corporation details a significant revenue increase and ongoing advancements in medical technology aimed at treating critical conditions.

CytoSorbents Announces Impressive Financial Growth in Second Quarter of 2025 #United_States #Princeton #CytoSorbents #DrugSorb-ATR #Blood_Purification

CytoSorbents Revolutionizes Sepsis Care with Innovative Blood Purification Solutions CytoSorbents Corporation shines a light on the crucial advancement in sepsis treatment, emphasizing the effectiveness of its CytoSorb® therapy while highlighting recent clinical studies.

CytoSorbents Revolutionizes Sepsis Care with Innovative Blood Purification Solutions #United_States #Princeton #Sepsis_Treatment #CytoSorbents #CytoSorb

CytoSorbents Shares Progress on DrugSorb-ATR Regulatory Pathway in U.S. and Canada CytoSorbents updates on its DrugSorb-ATR regulatory status with FDA and Health Canada, addressing critical bleeding issues in cardiac surgery.

CytoSorbents Shares Progress on DrugSorb-ATR Regulatory Pathway in U.S. and Canada #United_States #Princeton #CytoSorbents #DrugSorb-ATR #FDA_Update

CytoSorbents Appeals to FDA for De Novo Review of DrugSorb™-ATR Approval CytoSorbents Corporation has filed an appeal with the FDA regarding the denial of its DrugSorb-ATR device. The device aims to manage bleeding in cardiac surgeries.

CytoSorbents Appeals to FDA for De Novo Review of DrugSorb™-ATR Approval #United_States #Princeton #CytoSorbents #DrugSorb-ATR #FDA_Appeal

CytoSorbents to Showcase Innovations at Jefferies Global Healthcare Conference CytoSorbents Corporation will present at the Jefferies Global Healthcare Conference, highlighting its blood purification technologies that address critical conditions.

CytoSorbents to Showcase Innovations at Jefferies Global Healthcare Conference #USA #New_York #Healthcare_Conference #CytoSorbents #Blood_Purification

CytoSorbents Technology Dramatically Lowers Bleeding Risks in Urgent CABG Patients on Ticagrelor Recent data presented at EuroPCR 2025 shows that CytoSorbents' innovative blood purification technology significantly reduces severe bleeding during CABG surgeries for patients on Ticagrelor.

CytoSorbents Technology Dramatically Lowers Bleeding Risks in Urgent CABG Patients on Ticagrelor #United_States #Princeton #CytoSorbents #Ticagrelor #CABG

CytoSorbents Reports Financial Performance for Q1 2025 and Business Innovations CytoSorbents Corporation has reported its Q1 2025 financial results, highlighting revenue changes and strategic advancements in their business operations.

CytoSorbents Reports Financial Performance for Q1 2025 and Business Innovations #United_States #Princeton #FDA_Breakthrough #CytoSorbents #DrugSorb-ATR

CytoSorbents Updates on DrugSorb-ATR Regulatory Developments Following FDA Denial CytoSorbents provides an important regulatory update on DrugSorb-ATR, aiming to address severe bleeding during cardiac surgeries. FDA engagement continues.

CytoSorbents Updates on DrugSorb-ATR Regulatory Developments Following FDA Denial #United_States #Princeton #CytoSorbents #DrugSorb-ATR #FDA_Denial

CytoSorbents Corporation Secures $1.7 Million Via New Jersey Tax Program CytoSorbents Corporation has successfully secured approximately $1.7 million from the New Jersey Tax Certificate Transfer Program, bolstering its financial position and future growth.

CytoSorbents Corporation Secures $1.7 Million Via New Jersey Tax Program #United_States #Princeton #CytoSorbents #DrugSorb-ATR #NOL_Program

Melanie Grossman Joins CytoSorbents as Vice President and Corporate Controller CytoSorbents Corporation has named Melanie Grossman as Vice President and Corporate Controller, bringing over 25 years of experience in finance.

Melanie Grossman Joins CytoSorbents as Vice President and Corporate Controller #United_States #Princeton #CytoSorbents #DrugSorb-ATR #Melanie_Grossman

CytoSorbents Welcomes Thomas Shannon as New Marketing VP in North America Thomas Shannon has been appointed as the Vice President of Marketing for CytoSorbents in North America. His experience in critical care technology marks a significant step for the company.

CytoSorbents Welcomes Thomas Shannon as New Marketing VP in North America #United_States #Princeton,_NJ #CytoSorbents #DrugSorb-ATR #Thomas_Shannon

CytoSorbents Announces Extension of Series B Right Warrants Expiration Date CytoSorbents Corporation has announced a crucial extension of the expiration date for its Series B Right Warrants, enhancing its capital investment strategy. This adjustment could impact investors significantly.

CytoSorbents Announces Extension of Series B Right Warrants Expiration Date #USA #Princeton #Series_B #Warrants #CytoSorbents

CytoSorbents Achieves Notable Financial Progress in 2024 with Expanded Product Line and Regulatory Advancements CytoSorbents Corporation demonstrates significant revenue growth and strategic developments in 2024, paving the way for future regulatory approvals and market expansions.

CytoSorbents Achieves Notable Financial Progress in 2024 with Expanded Product Line and Regulatory Advancements #United_States #FDA_Approval #Princeton #CytoSorbents #DrugSorb-ATR